Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Nefrectomie bij gemetastaseerd niercelcarcinoom?
nov 2018 | Chirurgie, Uro-oncologie